広範囲小細胞肺がん市場：治療モダリティ、薬剤タイプ、投与経路、流通チャネル別-2025-2030年の世界予測

広範囲小細胞肺がん市場は、2023年に47億5,000万米ドルと評価され、2024年には54億米ドルに達すると予測され、CAGR 12.63％で成長し、2030年には109億2,000万米ドルに達すると予測されています。

広範囲小細胞肺がん（ES-SCLC）とは、小細胞肺がんの末期分類のひとつで、攻撃的な増殖と胸郭半部を超える広範な播種を特徴とし、しばしば遠隔臓器への浸潤を引き起こします。ES-SCLCの治療と診断の市場は、肺がんの世界の有病率の増加と、この疾患に関連する生存率が限られていることから、効果的な治療オプションの緊急の必要性によって牽引されています。治療革新の必要性は、予後が非常に悪いことと、がん細胞が急速に進化する性質にあり、免疫チェックポイント阻害剤、標的治療薬、先進ドラッグデリバリーシステムなどの新規治療薬の適用に適した領域となっています。これらの技術革新は、患者中心の治療と、腫瘍学ポートフォリオの拡大を目指す製薬・バイオテクノロジー業界の広範な活動にとって極めて重要です。この市場に影響を与える主な成長要因としては、分子生物学とゲノミクスの進歩により、よりオーダーメイドの治療やコンパニオン診断が可能になったこと、政府機関や民間団体によるがん研究への多額の投資が挙げられます。潜在的なビジネスチャンスとしては、AIを活用した診断ツールや個別化医療などの新技術が、患者の転帰の改善や医薬品開発プロセスの合理化につながる道を示しています。しかし、研究開発コストの高さ、規制要件の厳しさ、個別化治療プロトコルの複雑さといった課題が大きな障壁となっています。市場関係者は、こうした課題を軽減し、専門知識を共有するために、共同研究やパートナーシップに注力すべきです。イノベーションは、低侵襲の診断技術や、新しい分子標的を確立された治療法と統合する併用療法の開発を優先すべきです。さらに、新興諸国における最先端治療へのアクセスしやすさと手ごろさを向上させることは、市場開拓の重要な側面です。この市場の特徴は、急速な技術革新のサイクルと競合情勢の進展にあり、このダイナミックな情勢を先取りするためには、市場情報への積極的なアプローチが必要となります。

市場力学：急速に進化する広範囲小細胞肺がん市場の主要市場インサイトを公開

広範囲小細胞肺がん市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業組織は十分な情報に基づいた投資決定、戦略的決定の精緻化、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の広範囲小細胞肺がん普及率の上昇
  • ヘルスケア強化に関する意識の高まり
  • 広範囲小細胞肺がん治療に対する政府のイニシアチブの高まり
• 市場抑制要因
  • ジェネリック医薬品の氾濫
• 市場機会
  • 新しい治療法の研究開発分野における資金提供の増加
  • 広範囲小細胞肺がんスクリーニング手順の技術的進歩
• 市場の課題
  • 放射線療法や化学療法による副作用のリスク

ポーターのファイブフォース：広範囲小細胞肺がん市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：広範囲小細胞肺がん市場における外部からの影響の把握

外部マクロ環境要因は、広範囲小細胞肺がん市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析広範囲小細胞肺がん市場における競合情勢の把握

広範囲小細胞肺がん市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス広範囲小細胞肺がん市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、広範囲小細胞肺がん市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨広範囲小細胞肺がん市場における成功への道筋を描く

広範囲小細胞肺がん市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で広範囲小細胞肺がんの普及率が上昇
    • 強化された医療に関する意識の高まり
    • 広範囲小細胞肺がん治療に対する政府の取り組みの高まり
  • 抑制要因
    • ジェネリック医薬品の豊富な供給
  • 機会
    • 新しい治療の研究開発分野への資金提供の増加
    • 広範囲小細胞肺がんスクリーニング手順における技術的進歩
  • 課題
    • 放射線治療と化学療法の副作用のリスク
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 広範囲小細胞肺がん市場治療法別

• 化学療法
• 併用療法
• 免疫療法
• 放射線治療
• 標的療法

第7章 広範囲小細胞肺がん市場薬の種類別

• アテゾリズマブ
• デュルバルマブ
• エトポシド
• ルルビネクテジン
• メトトレキサート
• ペムブロリズマブ
• トポテカン

第8章 広範囲小細胞肺がん市場：投与経路別

• オーラル
• 非経口

第9章 広範囲小細胞肺がん市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの広範囲小細胞肺がん市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の広範囲小細胞肺がん市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの広範囲小細胞肺がん市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly & Company Ltd.
• Exelixis, Inc.
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Incyte Corporation
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Nektar Therapeutics
• Novartis AG
• Pfizer, Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

• FIGURE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET RESEARCH PROCESS
• FIGURE 2. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET DYNAMICS
• TABLE 7. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY LURBINECTEDIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TOPOTECAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 42. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 64. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. CHINA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 68. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. INDIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 137. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. ITALY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 153. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. POLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 157. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. QATAR EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 196. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. EXTENSIVE STAGE SMALL CELL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023

The Extensive Stage Small Cell Lung Cancer Market was valued at USD 4.75 billion in 2023, expected to reach USD 5.40 billion in 2024, and is projected to grow at a CAGR of 12.63%, to USD 10.92 billion by 2030.

Extensive Stage Small Cell Lung Cancer (ES-SCLC) refers to a late-stage classification of small cell lung cancer characterized by aggressive growth and widespread dissemination beyond the hemi-thorax, often leading to involvement of distant organs. The market for treatments and diagnostics for ES-SCLC is driven by the increasing prevalence of lung cancer worldwide and the urgent need for effective therapeutic options, given the limited survival rates associated with the disease. The necessity of treatment innovations lies in the dire prognosis and the rapidly evolving nature of the cancer cells, making this area ripe for the application of novel therapeutics such as immune checkpoint inhibitors, targeted therapies, and advanced drug delivery systems. These innovations are pivotal for both patient-centric treatments and the broad scope of pharmaceutical and biotech industries seeking to expand their oncology portfolios. Key growth factors influencing this market include advancements in molecular biology and genomics, enabling more tailored therapies and companion diagnostics, as well as significant investments in cancer research by governmental and private entities. As potential opportunities, emerging technologies such as AI-driven diagnostic tools and personalized medicine present avenues for enhanced patient outcomes and streamlined drug development processes. However, challenges such as the high costs of R&D, stringent regulatory requirements, and the complexity of personalized treatment protocols pose significant barriers. Market players should focus on collaborations and partnerships to mitigate these challenges and leverage shared expertise. Innovation should prioritize the development of minimally invasive diagnostic techniques and combination therapies that integrate new molecular targets with established treatment regimes. Additionally, increasing accessibility and affordability of cutting-edge treatments in developing countries represents a crucial aspect of market expansion. The nature of this market is characterized by rapid innovation cycles and competitive advancements, necessitating a proactive approach to market intelligence to stay ahead in this dynamic landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Extensive Stage Small Cell Lung Cancer Market

The Extensive Stage Small Cell Lung Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in prevalence of extensive stage small cell lung cancer across the globe
  • Growing awareness regarding enhanced health care
  • Rising government initiatives for extensive stage small cell lung cancer treatment
• Market Restraints
  • Huge availability of the generic drugs
• Market Opportunities
  • Increasing funding in the field of research and development of new treatment
  • Technological advancement in the extensive stage small cell lung cancer screening procedures
• Market Challenges
  • Risk of side effects of radiation and chemotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Extensive Stage Small Cell Lung Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Extensive Stage Small Cell Lung Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Extensive Stage Small Cell Lung Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Extensive Stage Small Cell Lung Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Extensive Stage Small Cell Lung Cancer Market

A detailed market share analysis in the Extensive Stage Small Cell Lung Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Extensive Stage Small Cell Lung Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Extensive Stage Small Cell Lung Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Extensive Stage Small Cell Lung Cancer Market

A strategic analysis of the Extensive Stage Small Cell Lung Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Extensive Stage Small Cell Lung Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly & Company Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson & Johnson Services, Inc., Merck KGaA, Nektar Therapeutics, Novartis AG, Pfizer, Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Extensive Stage Small Cell Lung Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Modalities, market is studied across Chemotherapy, Combination Therapies, Immunotherapy, Radiation Therapy, and Targeted Therapies.
• Based on Drug Type, market is studied across Atezolizumab, Durvalumab, Etoposide, Lurbinectedin, Methotrexate, Pembrolizumab, and Topotecan.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in prevalence of extensive stage small cell lung cancer across the globe
    • 5.1.1.2. Growing awareness regarding enhanced health care
    • 5.1.1.3. Rising government initiatives for extensive stage small cell lung cancer treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Huge availability of the generic drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing funding in the field of research and development of new treatment
    • 5.1.3.2. Technological advancement in the extensive stage small cell lung cancer screening procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of side effects of radiation and chemotherapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Extensive Stage Small Cell Lung Cancer Market, by Treatment Modalities

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Combination Therapies
• 6.4. Immunotherapy
• 6.5. Radiation Therapy
• 6.6. Targeted Therapies

7. Extensive Stage Small Cell Lung Cancer Market, by Drug Type

• 7.1. Introduction
• 7.2. Atezolizumab
• 7.3. Durvalumab
• 7.4. Etoposide
• 7.5. Lurbinectedin
• 7.6. Methotrexate
• 7.7. Pembrolizumab
• 7.8. Topotecan

8. Extensive Stage Small Cell Lung Cancer Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Extensive Stage Small Cell Lung Cancer Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Extensive Stage Small Cell Lung Cancer Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Extensive Stage Small Cell Lung Cancer Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Extensive Stage Small Cell Lung Cancer Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Boehringer Ingelheim GmbH
• 6. Bristol Myers Squibb Company
• 7. Celgene Corporation
• 8. Daiichi Sankyo Company, Limited
• 9. Eisai Co., Ltd.
• 10. Eli Lilly & Company Ltd.
• 11. Exelixis, Inc.
• 12. F. Hoffmann-La Roche AG
• 13. Genentech, Inc.
• 14. Gilead Sciences, Inc.
• 15. GlaxoSmithKline PLC
• 16. Incyte Corporation
• 17. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• 18. Johnson & Johnson Services, Inc.
• 19. Merck KGaA
• 20. Nektar Therapeutics
• 21. Novartis AG
• 22. Pfizer, Inc.
• 23. Sanofi S.A.
• 24. Takeda Pharmaceutical Co. Ltd.